drugset / Trial / NCT01753570
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
Timeline
- Start
- 2012-12
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon-beta | Protein / enzyme biologic | 6e+08 iu | — |
| Subject | RBV | Unknown | 600 mg | — |
| Subject | RBV | Unknown | 1000 mg | — |
| Subject | Telaprevir | Small molecule | 750 mg | — |